TITLE

Delayed Progression to Death and to AIDS in a Hong Kong Cohort of Patients with Advanced HIV Type 1 Disease During the Era of Highly Active Antiretroviral Therapy

AUTHOR(S)
Ka Hing Wong; Kenny Chi Wai Chan; Shui Shan Lee
PUB. DATE
September 2004
SOURCE
Clinical Infectious Diseases;9/15/2004, Vol. 39 Issue 6, p853
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. The magnitude of the impact of highly active antiretroviral therapy (HAART) since its introduction in non-Western countries is not entirely clear. We studied disease progression among adult patients with advanced human immunodeficiency virus type 1 (HIV-1) infection in the pre-HAART (i.e., 1996 and earlier) and HAART eras in Hong Kong. Methods. The cohort of patients seen at the integrated Treatment Center (Hong Kong) from 1984 through mid-2003 was retrospectively examined with respect to 3 clinical end points: death after the diagnosis of acquired immunodeficiency syndrome (AIDS), progression to AIDS after achieving a CD4 cell count of <200 cells/pt, and death after achieving a CD4 cell count of <200 cells/μL. Results. A total of 581 patients with advanced HIV- 1 disease had AIDS and/or a CD4 cell count of <200 cells/μL. The incidences of death after AIDS (52.3% vs. 13.6%), AIDS progression after a CD4 cell count of <200 cells/pt (47.7% vs. 20.9%), and death after a CD4 cell count of <200 cells/pt (38.8% vs. 7.0%) were significantly higher among patients in the pre-HAART era than among those in the HAART era (P< .001 for all). On the basis of life-table analysis, the probabilities of death after AIDS (Pc .0001), AIDS after a CD4 cell count of <200 cells! itL (P = .0063), and death after a CD4 cell count of <200 cells/pt (Pc .0001) diminished in the HAART era, compared with the pre-HAART era. Median survival after AIDS increased from 29.8 months during the pre- HAART era to >70 months during the HAART era (P < .001). Compared with patients in the pre-HAART era, adjusted hazard ratios of clinical events were 0.15 (95% confidence interval [CI], 0.08-0.26) for death after AIDS, 0.38 (95% CI, 0.24-0.60) for AIDS after a CD4 cell count of <200 cells/pt, and 0.25 (95% CI, 0.15-0.40) for death after a CD4 cell count of <200 cells/pt for patients in the HAART era. Conclusions. The clinical outcome of patients with advanced HIV- 1 disease in Hong Kong significantly improved during the HAART era. Our findings of extended durations of survival and AIDS-free status may be relevant to the expected health impacts associated with increased access to HAART in non-Western countries.
ACCESSION #
14384699

 

Related Articles

  • Adherence to Antiretroviral Therapy: How Much Is Enough? Gulick, Roy M. // Clinical Infectious Diseases;10/1/2006, Vol. 43 Issue 7, p942 

    The article presents a study on the efficiency of the antiretroviral therapy. It has been stated that the development of effective antiretroviral therapy in the resulted to significant virologic suppression and immune reconstitution and resulted in dramatic reductions in HIV-related morbidity...

  • Uptake of HIV testing and treatment in an isolated population with access to free and universal healthcare. Gillieatt, Sue J.; Mallal, Simon A.; Gillieatt, S J; Mallal, S A // International Journal of STD & AIDS;May2000, Vol. 11 Issue 5, p303 

    This Western Australian study analysed clinical information from 344 people with AIDS, and experiential data from a sample of 36 people with AIDS to investigate 2 relevant issues: the timing of HIV testing and uptake and experiences of HIV drug treatment. We found that the proportion of people...

  • CD4+ Count—Guided Interruption of Antiretroviral Treatment.  // New England Journal of Medicine;11/30/2006, Vol. 355 Issue 22, p2283 

    Background: Despite declines in morbidity and mortality with the use of combination antiretroviral therapy, its effectiveness is limited by adverse events, problems with adherence, and resistance of the human immunodeficiency virus (HIV). Methods: We randomly assigned persons infected with HIV...

  • Adherence to Antiretroviral Therapy in Patients Participating in a Graduated Cost Recovery Program at an HIV Care Center in South India. Batavia, Ashita S.; Balaji, Kavitha; Houle, Elizabeth; Parisaboina, Sangeetha; Ganesh, A. K.; Mayer, Kenneth H.; Solomon, Suniti // AIDS & Behavior;Aug2010, Vol. 14 Issue 4, p794 

    In resource-constrained settings, the most frequently cited barrier to optimal antiretroviral therapy (ART) adherence among HIV-infected patients has been the cost of medications. In recent years many subsidized medication programs have been developed to improve ART affordability. A Graduated...

  • Adherence to Antiretroviral Therapy Among HIV-Infected Drug Users: A Meta-Analysis. Malta, Monica; Magnanini, Monica M. F.; Strathdee, Steffanie A.; Bastos, Francisco I. // AIDS & Behavior;Aug2010, Vol. 14 Issue 4, p731 

    We conducted a meta-analysis of studies assessing adherence to highly active antiretroviral therapy (HAART) and a qualitative systematic review of factors associated with better HAART outcomes among HIV+ drug users (DU). Thirty-eight studies were considered, which analyzed 14,960 patients...

  • Corroborative Study Confirmed That Adding Enfuvirtide to an Optimized Antiretroviral Regimen Benefited Patients with Multidrug-Resistant HIV Infection. Lorber, Bennett // Annals of Internal Medicine;12/7/2004, Vol. 141 Issue 11, p878 

    The article presents information on papers related to infectious diseases in Europe and Australia. The paper "Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia," by A. Lazzarin, B. Clotet, D. Cooper, et al. confirmed that adding enfuvirtide to an...

  • Long-Term Remission in Progressive Multifocal Leukoencephalopathy Caused by Idiopathic CD4+ T Lymphocytopenia: A Case Report. Rueger, M. A.; Miletic, H.; Dorries, K.; Wyen, C.; Eggers, C.; Deckert, M.; Faetkenheuer, G.; Jacobs, A. H. // Clinical Infectious Diseases;4/1/2006, Vol. 42 Issue 7, pE53 

    Progressive multifocal leukoencephalopathy is caused by JC virus, an opportunistic infection of the central nervous system. Antiretroviral treatment for progressive multifocal leukoencephalopathy in human immunodeficiency virus-infected patients is beneficial, but few data exist for patients who...

  • Oral Lesions of HIV Disease and HAART in Industrialized Countries. Hodgson, T. A.; Greenspan, D.; Greenspan, J. S. // Advances in Dental Research;Apr2006, Vol. 19 Issue 1, p57 

    The epidemiology of HIV-related oral disease in industrialized nations has evolved following the initial manifestations described in 1982. Studies from both the Americas and Europe report a decreased frequency of HIV-related oral manifestations of 10-50% following the introduction of HAART...

  • Pneumocystis jirovecii prophylaxis discontinuation based upon total lymphocyte count in HIV-infected adults treated with antiretroviral therapy. Cheung, C.; Shuter, J. // International Journal of STD & AIDS;Jun2010, Vol. 21 Issue 6, p406 

    Pneumocystis jirovecii pneumonia (PCP) prophylaxis may be discontinued when CD4 is ≥200 cells/mm³ for three months in response to highly active antiretroviral therapy (HAART). Unlike CD4, the total lymphocyte count (TLC) is inexpensive and widely available in resource-constrained...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics